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Identity 
Other names: Malignant nonchromaffin 
paraganglioma; Malignant organoid granular cell 
myoblastoma 
Clinics and pathology 
Embryonic origin 
The histogenesis of this tumour is still unknown, 
despite immunohistochemistry studies and electron 
microscopy. It may have a myogenic origin, and might 
be a variant of rhabdomyosarcoma. 
Epidemiology 
Rare tumour: represents less than 1% of soft tissues 
sarcomas of adults and 1-2% of soft tissues sarcomas in 
children. 
Occurs most often in the young adult, less frequently i  
children. 
Median age is 20 years in female patients, and 30 years 
in male patients. More frequently, patients are females 
(ratio M/F is 2/3). 
Clinics 
Involve the muscles and soft tissues, in particular those 
of the lower extremities (buttocks, thighs and legs). 
This represents more than half cases in the adults. It 
may also arise in the upper extremities, in the head and 
neck regions, especially in the child, but it can also 
have extra muscular localizations, such as the female 
genital tract, the trunk, the mediastinum, or the 
retroperitoneum. 
Metastases are frequent. They occur mainly in lungs, 
bones, and brain. 
Symptoms at diagnosis may be pain and/or swelling. 
Diagnosis is often retarded. 
Pathology 
Well circumscribed tumours with a multinodular 
pattern, haemorrhagic and necrotic. 
Microcopically, exhibits an alveolar structure, the 
center of the alveolar space being formed by 
detachment of necrotic cells, and with surronding 
capillaries (there is a more solid pattern in children). 
Cells are large, with abundant cytoplasm. Mitoses are 
rare. 
Secretory process with the formation of cytoplasmic 
membrane-bound crystals (PAS+, diastase resistant) 
can often be seen with electron microscopy, a featur  of 
great diagnostic value (they are pathognomic). These 
granules contain monocarboxylate transporter 1 
(MCT1) - CD147 complexes. 
Immunochemistry: in general, alveolar soft part 
sarcomas are negative for neuroendocrin and epithelial 
markers, and often positive for vimentin, muscle-
specific actin, and desmin. The strong nuclear staining 
of an anti C-term TFE3 can be used for diagnosis 
(although cytogenetics and/or molecular genetics are 
the most relevant tools for diagnosis). 
To be noted is that a subset of renal cell carcinomas, 
the primary renal ASPSCR1-TFE3 tumour, share some 
morphological features with the alveolar soft part 
sarcoma (it may be a differential diagnosis); they also 
share a common genetic substratum. 
Treatment 
Primary tumours: large surgical excision (a complete 
resection is of great importance) and radiation. 
Metastases: chemotherapy, with or without radiation or 
surgery, depending on the number of metastases. 
Evolution 
Slow growing tumour, but highly angiogenic, which 
favours metastases dissemination. 






Atlas Genet Cytogenet Oncol Haematol. 2008;12(3)  251 
Metastases appear in more than half of the patients who 
presented without metastases at diagnosis (up to 70% in 
one study); however, there is a long disease-free 
interval before appearence of metastases (median 6 
years) in these patients. 
Prognosis 
Relatively indolent clinical course. In one study, 
overall survival of adult patients without metastases 
reached 87% at 5 years, but that of adult patients with 
metastases at diagnosis was only 20% at 5 years, with a 
median survival of 40 mths. Pediatric cases had a better 
prognosis, with a 5 years survival of 80% for all cases 
included, reaching 91% in cases without metastases. 
Median survival in patients without metastases at 
diagnosis was noted above 10 years in a large -but old 
(period 1923-1986)- study, and it may be expected that 
progress has been made. Due to the rarity of the disease 
and its long course, survival data are outdated. 
Cytogenetics 
Cytogenetics morphological  
t(X;17)(p11;q25) is found in all alveolar soft part 
sarcomas so far studied, but also in primary renal 
ASPSCR1-TFE3 tumours. In the case of alveolar soft 
part sarcoma, the chromosome rearrangement is found 
in an unbalanced form, as a der(17)t(X;17)(p11;q25), in 
80% of cases;  
the unbalanced form implicates:  
1- the formation of a hybrid gene at the breakpoint, bu  
also,  
2- gain in Xp11-pter sequences, and loss of 
heterozygocity in 17q25-qter, with possible 
implications, although no clinical (including 
prognostic) nor pathological differences have so far 
been noted between balanced and unbalanced cases... 
but, again, the disease is rare, and cases with 
cytogenetic studies even rarer (about 25 cases). 
Note: the t(X;17)(p11;q25) in primary renal 
ASPSCR1-TFE3 tumours is balanced in all known 
cases. 
Genes involved and Proteins 
Note: Retention of heterozygocity in the tumours of 
female patients (i.e. a normal maternal X and a normal 
paternal X are present, in addition to the Xp11-pter 
involved in the translocation) has been noted in all 
(n=7) female cases studied, showing that the 







Transcription factor; member of the basic helix-loop-
helix family (b-HLH) of transcription factors primarily 





Contains an UBX domain, ASPSCR1 binds SLC2A4 
(solute carrier family 2 (facilitated glucose transporter), 
member 4, also called GLUT4) endocytosed from the 
plasma membrane into vesicles. SLC2A4 is retained i 
the cell by ASPSCR1 in the absence of insulin. Insuli  
stimulates the release of retained SLC2A4 to 
exocytosis, allowing the rapid mobilization of glucose 
transporters to the cell surface. 




5' ASPSCR1 - 3' TFE3; the reciprocal 5' TFE3 - 3' 
ASPSCR1 is most often absent. ASPSCR1 is fused in 
frame either to TFE3 exon 3 or to exon 4 (type 1 and
type 2 fusions respectively). 
Fusion protein 
Description 
234 NH2 term amino acids from ASPSCR1, fused to 
the 280 or 315 C term amino acids from TFE3, 
including the activation domain, the helix-loop-helix, 
and the leucine zipper from TFE3. 
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